Maria Do Socorro de Mendonça Cavalcanti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Maria Do Socorro de Mendonça Cavalcanti has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Andreia Soares da Silva
Universidade de Pernambuco
6 shared publications - Isabela Cristina Cordeiro Farias
Universidade de Pernambuco
6 shared publications - Kleyton Palmeira Do Ó
Aggeu Magalhães Institute, Oswaldo Cruz Foundation (Fiocruz), Recife, Brasil
6 shared publications - Luydson Richardson Silva Vasconcelos
Instituto Aggeu Magalhães, Fundação Oswaldo Cruz, Recife, Brazil
6 shared publications - Taciana Furtado de Mendonça Belmont
Universidade de Pernambuco
6 shared publications - Ana Karla da Silva Freire
Universidade Federal Rural de Pernambuco
4 shared publications
Latest Publications
- 1 February 2023
- Published by Springer Nature in Molecular Biology Reports
- Vol. 50 (4) , 3341-3353
Polymorphisms and gene expression of metalloproteinases and their inhibitors associated with cerebral ischemic stroke in young patients with sickle cell anemia
Background Sickle cell anemia (SCA) is a genetic disease with great clinical heterogeneity and few viable strategies for treatment; hydroxyurea (HU) is the only widely used drug. Thus, the study of single nucleotide polymorphisms (SNPs) and the gene expression of MMPs 1, 2, 9, 7 and TIMPs 1 and 2, which are involved in the regulation of extracellular matrix, inflammation, and neuropathies, may provide further insights into the pathophysiology of the disease and elucidate biomarkers and molecules as potential therapeutic targets for patients with SCA. Methods and results We evaluated 251 young individuals with SCA from northeastern Brazil. The groups were divided according to vaso-occlusive crisis (VOC) and cerebrovascular disease (CVD), compared to control individuals. SNP detection and gene expression assays were performed by real-time PCR, TaqMan system®. Both the expression levels of MMP1 gene, and the SNP MMP1-1607 1G/2G were associated with the risk of cerebral ischemic stroke (IS), and the expression of MMP1 was also associated with a higher frequency of VOC/year. Expression levels of MMP7, TIMP1, and TIMP2 were increased in patients conditioned to IS. The SNP 372T>C (rs4898) TIMP1 T alleles were more frequent in patients with > 5 VOC events/year. The SNP rs17576 of MMP9 showed differences in gene expression levels; it was increased in the genotypes AG, and AG+GG. Conclusion The findings of this study, the SNPs, and expression provide initial support for understanding the role of MMPs-TIMPs in the pathophysiology of SCA in young patients.
- 1 February 2023
- Published by Springer Nature in Molecular Biology Reports
- Vol. 50 (4) , 3341-3353
Polymorphisms and gene expression of metalloproteinases and their inhibitors associated with cerebral ischemic stroke in young patients with sickle cell anemia
Background Sickle cell anemia (SCA) is a genetic disease with great clinical heterogeneity and few viable strategies for treatment; hydroxyurea (HU) is the only widely used drug. Thus, the study of single nucleotide polymorphisms (SNPs) and the gene expression of MMPs 1, 2, 9, 7 and TIMPs 1 and 2, which are involved in the regulation of extracellular matrix, inflammation, and neuropathies, may provide further insights into the pathophysiology of the disease and elucidate biomarkers and molecules as potential therapeutic targets for patients with SCA. Methods and results We evaluated 251 young individuals with SCA from northeastern Brazil. The groups were divided according to vaso-occlusive crisis (VOC) and cerebrovascular disease (CVD), compared to control individuals. SNP detection and gene expression assays were performed by real-time PCR, TaqMan system®. Both the expression levels of MMP1 gene, and the SNP MMP1-1607 1G/2G were associated with the risk of cerebral ischemic stroke (IS), and the expression of MMP1 was also associated with a higher frequency of VOC/year. Expression levels of MMP7, TIMP1, and TIMP2 were increased in patients conditioned to IS. The SNP 372T>C (rs4898) TIMP1 T alleles were more frequent in patients with > 5 VOC events/year. The SNP rs17576 of MMP9 showed differences in gene expression levels; it was increased in the genotypes AG, and AG+GG. Conclusion The findings of this study, the SNPs, and expression provide initial support for understanding the role of MMPs-TIMPs in the pathophysiology of SCA in young patients.
- 29 April 2021
- Published by SAGE Publications in AIDS Research and Human Retroviruses
- Vol. 37 (5) , 399-406
The 1G/1G+1G/2G Genotypes of MMP1 rs1799750 Are Associated with Higher Levels of MMP-1 and Are Both Associated with Lipodystrophy in People Living with HIV on Antiretroviral Therapy
In HIV-infected patients, antiretroviral therapy (ART) is associated to adipose tissue redistribution known as lipodystrophy (LD). This study aimed at verifying the association between the polymorphism of the MMP1 gene (rs1799750) (1G/2G) and the serum levels of matrix metalloproteinase 1 (MMP-1) with LD and its subtypes in people living with HIV on ART. This is a cross-secional study. LD was self-reported. The determination of the MMP1 rs1799750 gene polymorphism was performed by real-time PCR, and the serum concentrations of MMP-1 were quantified by the enzyme-linked immunosorbent assay (ELISA) method. Of 404 participants, 204 (51%) were diagnosed with LD, of whom 89 (43%) had mixed lipodystrophy (ML), 72 (35%) had lipohypertrophy (LH), and 43 (22%) had lipoatrophy (LA). There was an association between the genotypes 1G/1G+1G/2G and higher serum levels of MMP-1 ( p = .025). There was no association of MMP1 (1G/2G) with LD. Other factors associated with LD were current CD4 ≤ 350 [odds ratio (OR) = 4.85, confidence interval (CI) = 1.78–47.99, p = .0033] and serum MMP-1 levels >6.81 (OR = 2.67, CI = 1.21–6.08, p = .0165). Factors associated with ML: current CD4 ≤ 350 (OR = 5.59, CI = 1.69–20.39, p = .006); with LH: number of antiretroviral regimens used: 2 (OR = 2.06, CI = 1.01–4.20, p = .0460) and 3+ (OR = 2.09, CI = 1.00–4.35, p = .0477), and current CD4 ≤ 350 (OR = 2.08, CI = 1.00–4.24, p = .0461); and with LA: current viral load >40 (OR = 2.52, CI = 1.03–5.91, p = .0372) and current use of zidovudine (OR = 2.97, CI = 1.32–6.54, p = .0074). Higher levels of MMP-1 were associated with genotypes 1G/2G+1G/1G and with LD. Other individual risk factors were independently associated with LD, and its subtypes, suggesting that the pathogenesis itself is differently manifested for each type of LD.
- 29 April 2021
- Published by SAGE Publications in AIDS Research and Human Retroviruses
- Vol. 37 (5) , 399-406
The 1G/1G+1G/2G Genotypes of MMP1 rs1799750 Are Associated with Higher Levels of MMP-1 and Are Both Associated with Lipodystrophy in People Living with HIV on Antiretroviral Therapy
In HIV-infected patients, antiretroviral therapy (ART) is associated to adipose tissue redistribution known as lipodystrophy (LD). This study aimed at verifying the association between the polymorphism of the MMP1 gene (rs1799750) (1G/2G) and the serum levels of matrix metalloproteinase 1 (MMP-1) with LD and its subtypes in people living with HIV on ART. This is a cross-secional study. LD was self-reported. The determination of the MMP1 rs1799750 gene polymorphism was performed by real-time PCR, and the serum concentrations of MMP-1 were quantified by the enzyme-linked immunosorbent assay (ELISA) method. Of 404 participants, 204 (51%) were diagnosed with LD, of whom 89 (43%) had mixed lipodystrophy (ML), 72 (35%) had lipohypertrophy (LH), and 43 (22%) had lipoatrophy (LA). There was an association between the genotypes 1G/1G+1G/2G and higher serum levels of MMP-1 ( p = .025). There was no association of MMP1 (1G/2G) with LD. Other factors associated with LD were current CD4 ≤ 350 [odds ratio (OR) = 4.85, confidence interval (CI) = 1.78–47.99, p = .0033] and serum MMP-1 levels >6.81 (OR = 2.67, CI = 1.21–6.08, p = .0165). Factors associated with ML: current CD4 ≤ 350 (OR = 5.59, CI = 1.69–20.39, p = .006); with LH: number of antiretroviral regimens used: 2 (OR = 2.06, CI = 1.01–4.20, p = .0460) and 3+ (OR = 2.09, CI = 1.00–4.35, p = .0477), and current CD4 ≤ 350 (OR = 2.08, CI = 1.00–4.24, p = .0461); and with LA: current viral load >40 (OR = 2.52, CI = 1.03–5.91, p = .0372) and current use of zidovudine (OR = 2.97, CI = 1.32–6.54, p = .0074). Higher levels of MMP-1 were associated with genotypes 1G/2G+1G/1G and with LD. Other individual risk factors were independently associated with LD, and its subtypes, suggesting that the pathogenesis itself is differently manifested for each type of LD.
- Open Access
- 25 April 2021
- Published by Research, Society and Development in Research, Society and Development
- Vol. 10 (5)
Gasser cell: A biomarker of response to enzyme replacement therapy in patients with mucopolysaccharidosis type VI
The mucopolysaccharidosis (MPS) type VI is a rare lysosomal storage disease presenting leukocyte inclusions (Alder-Reilly anomaly) and lymphocytes with metachromatic inclusion surrounded by clear spaces, Gasser cells. Currently, an enzyme replacement therapy (ERT) with galsulfase is used to treat MPS type VI. This study evaluated 14 patients with MPS type VI performed cell counts Gasser before and after six months from the beginning of ERT. It was observed an average of 12.7% cells per patient, and after six months was found complete cell Gasser disappearance, proving to be an effective biomarker of response to ERT.
- 25 April 2021
- Published by Research, Society and Development in Research, Society and Development
- Vol. 10 (5)
Open AccessGasser cell: A biomarker of response to enzyme replacement therapy in patients with mucopolysaccharidosis type VI
The mucopolysaccharidosis (MPS) type VI is a rare lysosomal storage disease presenting leukocyte inclusions (Alder-Reilly anomaly) and lymphocytes with metachromatic inclusion surrounded by clear spaces, Gasser cells. Currently, an enzyme replacement therapy (ERT) with galsulfase is used to treat MPS type VI. This study evaluated 14 patients with MPS type VI performed cell counts Gasser before and after six months from the beginning of ERT. It was observed an average of 12.7% cells per patient, and after six months was found complete cell Gasser disappearance, proving to be an effective biomarker of response to ERT.
- Open Access
- 1 January 2021
- Published by INSTICC
- p. 51-62
Identifying Suspects on Social Networks: An Approach based on Non-structured and Non-labeled Data
- 1 January 2021
- Published by INSTICC
- p. 51-62
Open AccessIdentifying Suspects on Social Networks: An Approach based on Non-structured and Non-labeled Data
- Open Access
- 7 August 2020
- Published by Research, Society and Development in Research, Society and Development
- Vol. 9 (9) , e442997314
LGALS3 +191A and +292C polymorphisms are associated with a reduction in serum gal-3 levels, but not with the clinical events of individuals with sickle cell anemia
Objective: This study aimed to evaluate whether the single nucleotide polymorphisms (SNPs) +191 C>A (rs4644) and +292 A>C (rs4652) of the LGALS3 gene and the serum levels of galectin-3 (gal-3) are associated with clinical events in patients with sickle cell anemia (SCA). Methods: SNP +191 and +292 of the LGALS3 gene were detected by the TaqMan PCR system in real time. Gal-3 levels were measured in serum by ELISA. The study included 322 patients, mean age 36 (21-84). Results: AA and CA genotypes of the +191 region were related to lower levels of gal-3 when compared to CC genotype (p=0.0296). Lower level of gal-3 was also associated with the +191/+292 (AA/CC; CA/CC) diplotypes (p=0.0137) compared to the diplotypes (CC/AA; CC/CC; CC/AC; CA/AC). There was no association between serum levels of galectin-3 and genotype frequencies of the LGALS3 +191 and +292 polymorphisms with clinical events in SCA. Conclusion: The polymorphisms +191 and +292 of the LGALS3 are associated to decrease in serum levels of gal-3. However, no association of polymorphisms and levels of gal-3 with clinical events was observed in patients SCA.
- 7 August 2020
- Published by Research, Society and Development in Research, Society and Development
- Vol. 9 (9) , e442997314
Open AccessLGALS3 +191A and +292C polymorphisms are associated with a reduction in serum gal-3 levels, but not with the clinical events of individuals with sickle cell anemia
Objective: This study aimed to evaluate whether the single nucleotide polymorphisms (SNPs) +191 C>A (rs4644) and +292 A>C (rs4652) of the LGALS3 gene and the serum levels of galectin-3 (gal-3) are associated with clinical events in patients with sickle cell anemia (SCA). Methods: SNP +191 and +292 of the LGALS3 gene were detected by the TaqMan PCR system in real time. Gal-3 levels were measured in serum by ELISA. The study included 322 patients, mean age 36 (21-84). Results: AA and CA genotypes of the +191 region were related to lower levels of gal-3 when compared to CC genotype (p=0.0296). Lower level of gal-3 was also associated with the +191/+292 (AA/CC; CA/CC) diplotypes (p=0.0137) compared to the diplotypes (CC/AA; CC/CC; CC/AC; CA/AC). There was no association between serum levels of galectin-3 and genotype frequencies of the LGALS3 +191 and +292 polymorphisms with clinical events in SCA. Conclusion: The polymorphisms +191 and +292 of the LGALS3 are associated to decrease in serum levels of gal-3. However, no association of polymorphisms and levels of gal-3 with clinical events was observed in patients SCA.
- Open Access
- 23 April 2020
- Published by Research, Society and Development in Research, Society and Development
- Vol. 9 (7) , e439974240
MBL2 gene polymorphisms are not related to the occurrence of cerebrovascular disease in sickle cell anemia
Objective: This study has as objective to verify whether MBL2 gene polymorphisms are related to the occurrence of cerebrovascular disease (CD) in sickle cell anemia (SCA) patients. Methods: Overall, 259 unrelated SCA patients were enrolled. The patients were divided into three groups: control group, stroke group ad range of risk group. Peripheral blood samples were collected and DNA extraction was performed. All patients were genotyped for exon 1, promoter region -221 and promoter region -550 of MBL2 gene, along with β-globin gene haplotypes. Results: Concerning the genotyping of the MBL2, there was no difference in the frequency of allelic and genotypic variants of the exon 1 and the promoter regions -221 and -550 of the MBL2 gene among the studied groups. Conclusion: Despite the small number of patients, and the lack of association between MBL2 polymorphisms and CD, our study represents an effort to understand the impact of MBL2 polymorphisms in the clinical outcome of patients with SCA.
- 23 April 2020
- Published by Research, Society and Development in Research, Society and Development
- Vol. 9 (7) , e439974240
Open AccessMBL2 gene polymorphisms are not related to the occurrence of cerebrovascular disease in sickle cell anemia
Objective: This study has as objective to verify whether MBL2 gene polymorphisms are related to the occurrence of cerebrovascular disease (CD) in sickle cell anemia (SCA) patients. Methods: Overall, 259 unrelated SCA patients were enrolled. The patients were divided into three groups: control group, stroke group ad range of risk group. Peripheral blood samples were collected and DNA extraction was performed. All patients were genotyped for exon 1, promoter region -221 and promoter region -550 of MBL2 gene, along with β-globin gene haplotypes. Results: Concerning the genotyping of the MBL2, there was no difference in the frequency of allelic and genotypic variants of the exon 1 and the promoter regions -221 and -550 of the MBL2 gene among the studied groups. Conclusion: Despite the small number of patients, and the lack of association between MBL2 polymorphisms and CD, our study represents an effort to understand the impact of MBL2 polymorphisms in the clinical outcome of patients with SCA.
- Open Access
- 23 April 2020
- Published by Research, Society and Development in Research, Society and Development
- Vol. 9 (7) , e248974125
Cuidados paliativos em pessoas com carcinoma hepatocelular: uma revisão integrativa
Objetivo: analisar as estratégias de cuidado paliativo utilizadas por profissionais de saúde em pessoas com hepatocarcinoma. Método: revisão integrativa da literatura sobre o tema nas bases virtuais de dados Scielo, Lilacs, PubMed, MEDLINE e BDENF, sem restrição de idioma ou data de publicação. A busca foi realizada nos meses de janeiro e fevereiro de 2020. Resultados: os estudos apontaram escassez na produtividade científica na área, considerando que somente 12 artigos foram selecionados. Percebeu-se que as estratégias de cuidados paliativos utilizadas por profissionais de saúde são variadas e vão desde um tratamento individualizado a cada pessoa até o gerenciamento dos sintomas com abordagem nas necessidades físicas e psicossociais, com valorização da equipe multi/interprofissional. Conclusão: espera-se com este estudo incentivar outros profissionais de saúde a desenvolverem mais publicações para a obtenção de um conhecimento amplo, atualizado e relevante sobre estratégias no cuidado paliativo de pessoas com carcinoma hepatocelular.
- 23 April 2020
- Published by Research, Society and Development in Research, Society and Development
- Vol. 9 (7) , e248974125
Open AccessCuidados paliativos em pessoas com carcinoma hepatocelular: uma revisão integrativa
Objetivo: analisar as estratégias de cuidado paliativo utilizadas por profissionais de saúde em pessoas com hepatocarcinoma. Método: revisão integrativa da literatura sobre o tema nas bases virtuais de dados Scielo, Lilacs, PubMed, MEDLINE e BDENF, sem restrição de idioma ou data de publicação. A busca foi realizada nos meses de janeiro e fevereiro de 2020. Resultados: os estudos apontaram escassez na produtividade científica na área, considerando que somente 12 artigos foram selecionados. Percebeu-se que as estratégias de cuidados paliativos utilizadas por profissionais de saúde são variadas e vão desde um tratamento individualizado a cada pessoa até o gerenciamento dos sintomas com abordagem nas necessidades físicas e psicossociais, com valorização da equipe multi/interprofissional. Conclusão: espera-se com este estudo incentivar outros profissionais de saúde a desenvolverem mais publicações para a obtenção de um conhecimento amplo, atualizado e relevante sobre estratégias no cuidado paliativo de pessoas com carcinoma hepatocelular.
- Open Access
- 22 March 2020
- Published by Research, Society and Development in Research, Society and Development
- Vol. 9 (5) , e182953353
Assistência de enfermagem no manejo da dor em crianças com anemia falciforme: uma revisão integrativa
Objetivo: analisar as estratégias de cuidado de Enfermagem empregadas no manejo da dor em crianças com anemia falciforme. Método: revisão integrativa da literatura sobre o tema nas bases virtuais de dados Scielo, Lilacs, PubMed, MEDLINE e BDENF nos meses de janeiro e fevereiro de 2020. Resultados: foram selecionados 17 artigos e identificadas duas categorias analíticas: conhecimento dos profissionais e educação das crianças e familiares sobre o processo patológico da dor e tratamento farmacológico e não farmacológico para o manejo da dor. Conclusão: como estratégias no enfrentamento da dor em crianças há o tratamento farmacológico e não farmacológico adequado, além do conhecimento da Enfermagem que previne complicações, bem como a educação das crianças e familiares sobre a doença, que favorece a melhora e adaptação aos sintomas.
- 22 March 2020
- Published by Research, Society and Development in Research, Society and Development
- Vol. 9 (5) , e182953353
Open AccessAssistência de enfermagem no manejo da dor em crianças com anemia falciforme: uma revisão integrativa
Objetivo: analisar as estratégias de cuidado de Enfermagem empregadas no manejo da dor em crianças com anemia falciforme. Método: revisão integrativa da literatura sobre o tema nas bases virtuais de dados Scielo, Lilacs, PubMed, MEDLINE e BDENF nos meses de janeiro e fevereiro de 2020. Resultados: foram selecionados 17 artigos e identificadas duas categorias analíticas: conhecimento dos profissionais e educação das crianças e familiares sobre o processo patológico da dor e tratamento farmacológico e não farmacológico para o manejo da dor. Conclusão: como estratégias no enfrentamento da dor em crianças há o tratamento farmacológico e não farmacológico adequado, além do conhecimento da Enfermagem que previne complicações, bem como a educação das crianças e familiares sobre a doença, que favorece a melhora e adaptação aos sintomas.
- Open Access
- 1 October 2014
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- Vol. 2
Works in Progress Program Committee
Provides a listing of current committee members and society officers.
- 1 October 2014
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- Vol. 2
Open AccessWorks in Progress Program Committee
Provides a listing of current committee members and society officers.
- 1 September 2010
- Published by Elsevier in Human Immunology
- Vol. 71 (9) , 883-887
Association of hepatitis C virus infection and liver fibrosis severity with the variants alleles of MBL2 gene in a Brazilian population
- 1 September 2010
- Published by Elsevier in Human Immunology
- Vol. 71 (9) , 883-887
Association of hepatitis C virus infection and liver fibrosis severity with the variants alleles of MBL2 gene in a Brazilian population